Circulating Tumor DNA Evaluated by Next-Generation Sequencing Is Predictive of Tumor Response and Prolonged Clinical Benefit With Nivolumab in Advanced Non-Small Cell Lung Cancer
OncoImmunology - United States
doi 10.1080/2162402x.2018.1424675
Full Text
Open PDFAbstract
Available in full text
Date
January 29, 2018
Authors
Publisher
Informa UK Limited